<p>富国银行分析师本杰明·伯内特昨日对 Axsome Therapeutics 维持了买入评级，并设定了 157.00 美元的目标价。</p>
<h3>在 TipRanks Premium 上享受 50% 的折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>根据 TipRanks 的数据，伯内特的平均回报为-3.0%，成功率为 40.50%。伯内特覆盖医疗保健行业，专注于阿尔克梅斯、泽农和曼金德等股票。</p>
<p>除了富国银行，Axsome Therapeutics 还在 12 月 12 日获得了 RBC Capital 的列昂尼德·季马舍夫的买入评级。然而，在 12 月 9 日，TR | OpenAI – 4o 对 Axsome Therapeutics（NASDAQ: AXSM）重申了持有评级。</p>

AXSM

<p>Wells Fargo 分析师 Benjamin Burnett 对 Axsome Therapeutics 维持了买入评级，目标价为 157 美元。RBC Capital 也发布了买入评级，而 TR 重申了持有评级。Burnett 负责医疗保健行业，平均回报率为 -3.0%，成功率为 40.50%</p>

<p>Wells Fargo analyst Benjamin Burnett maintained a Buy rating on Axsome Therapeutics yesterday and set a price target of $157.00.</p>
<div class="lb-trans"><p>富国银行分析师本杰明·伯内特昨日对 Axsome Therapeutics 维持了买入评级，并设定了 157.00 美元的目标价。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 50% 的折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>According to TipRanks, Burnett is an analyst with an average return of -3.0% and a 40.50% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Alkermes, Xenon, and MannKind.</p>
<div class="lb-trans"><p>根据 TipRanks 的数据，伯内特的平均回报为-3.0%，成功率为 40.50%。伯内特覆盖医疗保健行业，专注于阿尔克梅斯、泽农和曼金德等股票。</p>
</div><p>In addition to Wells Fargo, Axsome Therapeutics also received a Buy from RBC Capital’s Leonid Timashev in a report issued on December 12. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on Axsome Therapeutics (NASDAQ: AXSM).</p>
<div class="lb-trans"><p>除了富国银行，Axsome Therapeutics 还在 12 月 12 日获得了 RBC Capital 的列昂尼德·季马舍夫的买入评级。然而，在 12 月 9 日，TR | OpenAI – 4o 对 Axsome Therapeutics（NASDAQ: AXSM）重申了持有评级。</p>
</div>

Axsome Therapeutics (AXSM) 获得了富国银行的买入评级